Compare Bank of Montreal (BMO) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bank of Montreal vs Neurocrine Biosciences Inc — how do they compare? Bank of Montreal trades at $180.98 (market cap $124.81B), while Neurocrine Biosciences Inc trades at $170.05 (market cap $17.51B). The key difference: Bank of Montreal is far larger — about 7.1× Neurocrine Biosciences Inc's market cap, and Bank of Montreal pays a 2.77% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| BMO | NBIX | |
|---|---|---|
Market Cap | $124.81B | $17.51B |
Sector | Financials | Health |
52-Week High | $180.86 | $180.55 |
52-Week Low | $110.44 | $123.10 |
Dividend Yield | 2.77% | — |
Enterprise Value | — | $16.60B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bank of Montreal
Bank of Montreal is a diversified financial-services provider based in North America, operating four business segments: Canadian personal and commercial banking, U.S. P&C banking, wealth management, and capital markets. The bank's operations are primarily in Canada, with a material portion also in the U.S.
Read more on BMO →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
